Cargando…
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available therapies. Enhancers of zeste homologue 1 and 2 (EZH1/2) are histone H3 lysine-27 trimethyltransferases (H3K27me3). Despite the rapid development of new drugs inhibiting EZH2 and/or EZH1, the molecula...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698684/ https://www.ncbi.nlm.nih.gov/pubmed/34944658 http://dx.doi.org/10.3390/biomedicines9121842 |
_version_ | 1784620335769845760 |
---|---|
author | Schümann, Franziska Lea Groß, Elisabeth Bauer, Marcus Rohde, Christian Sandmann, Sarah Terziev, Denis Müller, Lutz P. Posern, Guido Wienke, Andreas Fend, Falko Hansmann, Martin-Leo Klapper, Wolfram Rosenwald, Andreas Stein, Harald Dugas, Martin Müller-Tidow, Carsten Wickenhauser, Claudia Binder, Mascha Weber, Thomas |
author_facet | Schümann, Franziska Lea Groß, Elisabeth Bauer, Marcus Rohde, Christian Sandmann, Sarah Terziev, Denis Müller, Lutz P. Posern, Guido Wienke, Andreas Fend, Falko Hansmann, Martin-Leo Klapper, Wolfram Rosenwald, Andreas Stein, Harald Dugas, Martin Müller-Tidow, Carsten Wickenhauser, Claudia Binder, Mascha Weber, Thomas |
author_sort | Schümann, Franziska Lea |
collection | PubMed |
description | T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available therapies. Enhancers of zeste homologue 1 and 2 (EZH1/2) are histone H3 lysine-27 trimethyltransferases (H3K27me3). Despite the rapid development of new drugs inhibiting EZH2 and/or EZH1, the molecular interplay of these proteins and the impact on disease progression and prognosis of patients with T-cell lymphomas remains insufficiently understood. In this study, EZH1/2 mutation status was evaluated in 33 monomorphic epitheliotropic intestinal T-cell lymphomas by next generation sequencing and EZH1/2 and H3K27me3 protein expression levels were detected by immunohistochemistry in 46 T-cell lymphomas. Correlations with clinicopathologic features were analyzed and survival curves generated. No EZH1 mutations and one (3%) EZH2 missense mutation were identified. In univariable analysis, high EZH1 expression was associated with an improved overall survival (OS) and progression-free survival (PFS) whereas high EZH2 and H3K27me3 expression were associated with poorer OS and PFS. Multivariable analysis revealed EZH1 (hazard ratio (HR) = 0.183; 95% confidence interval (CI): 0.044–0.767; p = 0.020;) and EZH2 (HR = 8.245; 95% CI: 1.898–35.826; p = 0.005) to be independent, divergent prognostic markers for OS. In conclusion, EZH1/2 protein expression had opposing effects on the prognosis of T-cell lymphoma patients. |
format | Online Article Text |
id | pubmed-8698684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86986842021-12-24 Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas Schümann, Franziska Lea Groß, Elisabeth Bauer, Marcus Rohde, Christian Sandmann, Sarah Terziev, Denis Müller, Lutz P. Posern, Guido Wienke, Andreas Fend, Falko Hansmann, Martin-Leo Klapper, Wolfram Rosenwald, Andreas Stein, Harald Dugas, Martin Müller-Tidow, Carsten Wickenhauser, Claudia Binder, Mascha Weber, Thomas Biomedicines Article T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available therapies. Enhancers of zeste homologue 1 and 2 (EZH1/2) are histone H3 lysine-27 trimethyltransferases (H3K27me3). Despite the rapid development of new drugs inhibiting EZH2 and/or EZH1, the molecular interplay of these proteins and the impact on disease progression and prognosis of patients with T-cell lymphomas remains insufficiently understood. In this study, EZH1/2 mutation status was evaluated in 33 monomorphic epitheliotropic intestinal T-cell lymphomas by next generation sequencing and EZH1/2 and H3K27me3 protein expression levels were detected by immunohistochemistry in 46 T-cell lymphomas. Correlations with clinicopathologic features were analyzed and survival curves generated. No EZH1 mutations and one (3%) EZH2 missense mutation were identified. In univariable analysis, high EZH1 expression was associated with an improved overall survival (OS) and progression-free survival (PFS) whereas high EZH2 and H3K27me3 expression were associated with poorer OS and PFS. Multivariable analysis revealed EZH1 (hazard ratio (HR) = 0.183; 95% confidence interval (CI): 0.044–0.767; p = 0.020;) and EZH2 (HR = 8.245; 95% CI: 1.898–35.826; p = 0.005) to be independent, divergent prognostic markers for OS. In conclusion, EZH1/2 protein expression had opposing effects on the prognosis of T-cell lymphoma patients. MDPI 2021-12-05 /pmc/articles/PMC8698684/ /pubmed/34944658 http://dx.doi.org/10.3390/biomedicines9121842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schümann, Franziska Lea Groß, Elisabeth Bauer, Marcus Rohde, Christian Sandmann, Sarah Terziev, Denis Müller, Lutz P. Posern, Guido Wienke, Andreas Fend, Falko Hansmann, Martin-Leo Klapper, Wolfram Rosenwald, Andreas Stein, Harald Dugas, Martin Müller-Tidow, Carsten Wickenhauser, Claudia Binder, Mascha Weber, Thomas Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title | Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title_full | Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title_fullStr | Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title_full_unstemmed | Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title_short | Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas |
title_sort | divergent effects of ezh1 and ezh2 protein expression on the prognosis of patients with t-cell lymphomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698684/ https://www.ncbi.nlm.nih.gov/pubmed/34944658 http://dx.doi.org/10.3390/biomedicines9121842 |
work_keys_str_mv | AT schumannfranziskalea divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT großelisabeth divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT bauermarcus divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT rohdechristian divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT sandmannsarah divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT terzievdenis divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT mullerlutzp divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT posernguido divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT wienkeandreas divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT fendfalko divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT hansmannmartinleo divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT klapperwolfram divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT rosenwaldandreas divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT steinharald divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT dugasmartin divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT mullertidowcarsten divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT wickenhauserclaudia divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT bindermascha divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas AT weberthomas divergenteffectsofezh1andezh2proteinexpressionontheprognosisofpatientswithtcelllymphomas |